Stock Details
4523.T is Eisai Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 7,689.00¥. Average daily volumn in 3 months 1.88M. Market cap 2.09T



Stock symbol : 4523.T. Exchange : Tokyo. Currency : JPY
Lastest price : 7,302.00¥. Total volume : 668.20k. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Eisai Co., Ltd. (4523.T)
Last Price
7,302.00¥
Change
-1.00
Volume
668.20k

Previous Close7,303.00
Open7,366.00
Day Range7,262.00-7,383.00
Bid0.00 x N/A
Ask0.00 x N/A
Volume668.2k
Average Volume1.88M
Market Cap2.09T
Beta0.15
52 Week Range5,011.00-10,050.00
Trailing P/E19.49
Foward P/E42.58
Dividend (Yield %)2.19%
Ex-Dividend Date2023-03-30



Financial Details


According to Eisai Co., Ltd.'s financial reports the company's revenue in 2022 were 756.23B an increase( +17.21%) over the years 2021 revenue that were of 645.94B. In 2022 the company's total earnings were 47.95B while total earnings in 2021 were 42.12B( +11.9%).


Loading ...



Organization

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted... medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

eisai-co-ltd-logo

Market Cap:
2.09T
Revenue:
756.23B
Total Assets:
1.24T
Total Cash:
309.63B


News about "Eisai Co., Ltd."

Eisai Co Ltd

Source from : Reuters - 1 year ago

Healthcare & Pharmaceuticalscategory Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab, article with image March 6, 2023 Worldcategory FDA neurosciences chief Billy Dunn ...See details»


us-va-to-cover-eisai-biogen-alzheimers-treatment-leqembi-image

US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi

Source from : Reuters on MSN - 14 days ago

Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the ...See details»


Veterans Health to cover Eisai, Biogen’s new Alzheimer’s drug

Source from : MarketWatch on MSN - 14 days ago

Tuesday that the Veterans Health Administration will cover Leqembi, the Alzheimer’s disease treatment it developed with Biogen Inc. that received an accelerated approval in January. The drug is not ...See details»


Eisai Co Ltd ADR Stock (OTC:ESALY), Short Interest Report

Source from : Benzinga.com - 10 month ago

Short interest for Eisai Co Ltd ADR gives investors a sense of the degree to which investors are betting on the decline of Eisai Co Ltd ADR's stock. Short interest data is updated every two weeks.See details»


Eisai Co Ltd ADR Stock (OTC:ESALY), Analyst Ratings, Price Targets, Predictions

Source from : Benzinga.com - 14 days ago

Eisai Co Ltd ADR Stock (OTC:ESALY), Analyst Ratings, Price Targets, Predictions Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can ...See details»


Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer

Source from : Asia One - 4 days ago

Eisai Co., Ltd. announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa ...See details»


Client Profile: Eisai Co Ltd

Source from : OpenSecrets.org - 1 month ago

A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...See details»


EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL

Source from : Business Insider - 9 days ago

TOKYO, March 19, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced the publication of updated results from an evaluation estimating the societal ...See details»


Eisai Co., Ltd. (ESAIY)

Source from : Yahoo Finance - 14 days ago

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ ...See details»


Eisai Co Ltd ADR (ESALY)

Source from : Nasdaq - 3 years ago

© 2023 EDGAR®Online LLC, a subsidiary of OTC Markets Group. All rights reserved. EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission ...See details»


EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL

Source from : Mena FN - 9 days ago

(MENAFN- PR Newswire) TOKYO, March 19, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') today announced the publication of updated results from an evaluation ...See details»


US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi

Source from : Financial Post - 15 days ago

Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer’s treatment Leqembi to veterans at an early stage of the ...See details»


Eisai Co Ltd

Source from : OpenSecrets.org - 2 years ago

*Each quarterly filing is treated as a separate report. Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, ...See details»


US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi

Source from : health.economictimes.indiatimes - 14 days ago

Eisai Co Ltd and Biogen Inc said on Monday that the US Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory ...See details»